{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:55:30Z","timestamp":1764996930521},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T00:00:00Z","timestamp":1326412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is little clinical information on the management of hepatitis B virus (HBV) that is resistant to multiple drugs including entecavir (ETV). The present retrospective cohort study assessed the antiviral efficacy of ETV\/adefovir dipivoxil (ADV) combination therapy for ETV\u2010resistant HBV with prior lamivudine (LAM) resistance, and either with or without previous ADV resistance. The cumulative probability of achieving a virological response (undetectable serum HBV DNA) was compared by Kaplan\u2013Meier analysis and the Breslow method. Seventeen patients with ETV\u2010resistant HBV who were treated with ETV\/ADV combination therapy for at least 6 months at a tertiary care center, were included; seven had dual resistance to ETV and LAM [ADV\u2010r(\u2212) group] and 10 had triple resistance to ETV, LAM, and ADV [ADV\u2010r(+) group]. The median follow\u2010up period was 9 months (range, 6\u201323). A virological response was noted in seven patients after a median of 3 months (range, 3\u201312) of treatment; five in the ADV\u2010r(\u2212) group and two in the ADV\u2010r(+) group. The cumulative probability of a virological response was significantly higher in the ADV\u2010r(\u2212) group than in the ADV\u2010r(+) group (6 months cumulative probability, 57.1% vs. 11.1%). In conclusion, ETV\/ADV combination therapy led to virological responses in five of seven patients with resistance to ETV and LAM, but a significantly poorer response in patients with prior ADV resistance than in those without prior ADV resistance. Therefore, ETV\/ADV combination therapy could be a useful therapeutic option for ETV\u2010 and LAM\u2010resistant HBV without prior ADV resistance. J. Med. Virol. 84:424\u2013430, 2012. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/jmv.23229","type":"journal-article","created":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T19:53:34Z","timestamp":1326484414000},"page":"424-430","source":"Crossref","is-referenced-by-count":15,"title":["Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir\/lamivudine\u2010resistant hepatitis B virus with or without adefovir resistance"],"prefix":"10.1002","volume":"84","author":[{"given":"Hyo\u2010Joon","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong\u2010Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung\u2010Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo\u2010Suk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,13]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051285"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.055"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01306-10"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01161.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1417"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1561-2"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35352"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22900"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.020"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2006.01.003"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/321879"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1304"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1510"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3282f793d6"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22658"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.033"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21513"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-915644"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000252780"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.051"},{"key":"e_1_2_5_23_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","article-title":"In vitro susceptibility of adefovir\u2010associated hepatitis B virus polymerase mutations to other antiviral agents","volume":"12","author":"Qi X","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21534"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.033"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000081740"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00833-06"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22841"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2003.09.022"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.11.016"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20981"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.23229","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.23229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T17:48:20Z","timestamp":1700588900000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.23229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,13]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1002\/jmv.23229"],"URL":"https:\/\/doi.org\/10.1002\/jmv.23229","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,13]]}}}